Informations générales (source: ClinicalTrials.gov)
Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.
Observational
Institut Curie (Voir sur ClinicalTrials)
février 2008
29 juin 2024
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the
laboratory may help doctors learn more about changes that occur in DNA and identify
biomarkers related to cancer.
PURPOSE: This research study is looking at tumor and blood samples from women with breast
cancer.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | Paul-Henri Cottu | Contact (sur clinicalTrials) | |||
Critères
Femme
DISEASE CHARACTERISTICS:
- Diagnosis of infiltrating unilateral breast cancer
- No in situ disease (ductal or lobular)
- No invasive bilateral synchronous disease
- Breast cancer at high risk, defined by at least 2 of the following factors:
- Hormone receptor negative (HR-)
- Axillary node positive
- Histopathologic grade III
- High mitotic index (as defined by the Curie Institute as > 20 mitoses per 10
high-power fields [HPF])
- Tumor size ≥ 2 cm
- HER2-positive (3 + IHC or FISH/ICHS positive)
- Triple-negative tumors (HR- and HER2-negative)
- Initial thoracic-abdomino-pelvic and bone scans must be negative
- Underwent initial surgery
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Serum calcium normal (15.3 mg/dL) or normalized within 8 weeks after surgery
- No other invasive cancer within the past 5 years
- Not pregnant or nursing
- No psychological, familial, social, or geographical reasons that make monitoring
impossible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Diagnosis of infiltrating unilateral breast cancer
- No in situ disease (ductal or lobular)
- No invasive bilateral synchronous disease
- Breast cancer at high risk, defined by at least 2 of the following factors:
- Hormone receptor negative (HR-)
- Axillary node positive
- Histopathologic grade III
- High mitotic index (as defined by the Curie Institute as > 20 mitoses per 10
high-power fields [HPF])
- Tumor size ≥ 2 cm
- HER2-positive (3 + IHC or FISH/ICHS positive)
- Triple-negative tumors (HR- and HER2-negative)
- Initial thoracic-abdomino-pelvic and bone scans must be negative
- Underwent initial surgery
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Serum calcium normal (15.3 mg/dL) or normalized within 8 weeks after surgery
- No other invasive cancer within the past 5 years
- Not pregnant or nursing
- No psychological, familial, social, or geographical reasons that make monitoring
impossible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics